Navigo™ MR-ultrasound fusion guided biopsies

Despite limitations considering the presence, staging and aggressiveness of prostate cancer, ultrasonography (US)-guided systematic biopsies (SB) are still the 'golden standard' for the diagnosis of prostate cancer. Recently, promising results have been published for targeted prostate biopsies (TB) using magnetic resonance imaging (MRI) and ultrasonography (MRI/US)-fusion platforms. With help of image fusion we are able to navigate the ultrasound guided biopsies to the region of interest (ROI) found on MRI. This may lead to better and quicker diagnosis of prostate cancer. Furthermore there will be less delay in definitive treatment of people who are diagnosed with prostate cancer earlier. Possibly a more accurate Gleason grading can be obtained resulting in more accurate work-up and leading to a more tailored treatment advise.

We hypothesize that MRI guided targeted prostate biopsies are equal in finding prostate cancer as systematic biopsies, and even better at finding clinical relevant prostate cancer (>Gleason 6).

Both interventions will take place on the same day, in the same biopsy session.

In-patient control study.

Patients receive both interventions:

- conventional Navigo™-based systematic biopsies (12 cores)

- in case of region of interest on mpMRI: MR-US fusion targeted biopsies (max 4 cores)